Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
2024
2023
2022
2021
2020
2019
-
Sep 14,2023
HuidaGene Showcases Gene-Editing Based Medicine for Neurological Disease at Japan Society of Gene and Cell Therapy 2023 Annual Meeting
Learn More
-
Sep 06,2023
HuidaGene Therapeutics Announces First Patient Dosed Of The World's First Novel CRISPR/Cas13 RNA-Editing Therapy HG202 For Neovascular Age-related Macular Degeneration
Learn More
-
Aug 07,2023
HuidaGene Therapeutics Receives FDA Rare Pediatric Disease Designation for HG004 to Treat Inherited Blindness
Learn More
-
Aug 04,2023
HuidaGene and Kactus Announce Strategic Collaboration and License Agreement to Promote Commercialization of Next-Generation Gene Editing Enzyme, hfCas12Max®
Learn More
-
May 25,2023
HuidaGene Therapeutics Appoints Alvin Luk as Chief Executive Officer
Learn More
-
May 19,2023
NSR｜HuidaGene's Yang Hui team pioneers disruptive guanine (G) base editor
Learn More
-
May 03,2023
Huidagene Therapeutics Announces 19 Presentations Highlighting Advances in its Gene Therapy Technology Platforms at the 2023 ASGCT Annual Meeting
Learn More
-
Apr 18,2023
HuidaGene Announces IND Approval Of The First China Multinational Master Protocol of HG004 By China NMPA
Learn More
-
Apr 10,2023
HuidaGene Appoints New Members to the Scientific Advisory Board
Learn More